IP Library › Granted Patent US 12,440,482
Granted Patent B2
US 12,440,482 · App. 17/491,836 · Granted Oct 14, 2025

1,4-dihydropyridine compositions, methods of making and use

Inventors: Daniel Walter Wehrung (Johnstown, OH); Meng Zhong (Westerville, OH); Saral Pinkal Patel (Powell, OH); Bindhu Madhavi Rayaprolu (Columbus, OH)
Assignee: American Regent, Inc.
A61K31/4422A61K47/183
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,482
App. No.
17/491,836
Granted
Oct 14, 2025
Kind
B2
Abstract

Provided herein are pharmaceutical compositions comprising a class of calcium channel blockers and at least one chelating agent. More specifically, the pharmaceutical compositions comprise at least one 1,4-dihydropyridine (DHP) compound and at least one chelating agent. The chelating agents used in this disclosure can decrease the degradation of the constituent DHPs of the DHP compositions. The DHP compositions can be used to treat cardiovascular disorders and are more stable for prolonged periods of time.

Claims (27)

1. A sterile composition comprising nicardipine and a chelating agent, the chelating agent in an amount of 0.001 weight percent to 10 weight percent of the composition, wherein the composition is in a container and the chelating agent is ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTPA), deferoxamine mesylate or free bases, hydrates, solvates, crystalline polymorphs, amorphous forms or pharmaceutically acceptable salts thereof.

2. The composition of claim 1 , wherein the container comprises a vial, prefilled syringe, or ampule or the container comprises a vial having a barrier coated stopper.

3. The composition of claim 1 , wherein the pharmaceutical composition is a preservative-free, ready-to-use injectable aqueous formulation.

4. The composition of claim 1 , wherein the container is a sterile bag for intravenous infusion that is pre-mixed, ready-to-use and can be administered to a patient.

5. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier comprising water and the composition is enclosed in a single-use container having a volume of from about 1 mL to about 200 mL.

6. The composition of claim 1 , wherein the composition is a lyophilized dry powder which can be reconstituted in water, saline, dextrose, or mixtures thereof for injection.

7. The composition of claim 1 , wherein the nicardipine is nicardipine hydrochloride.

8. A method of treating at least one cardiovascular disorder in a human, the method comprising administering to the human a therapeutically effective amount of a pharmaceutical composition comprising nicardipine in an amount of at least 0.1 weight percent of the composition and at a chelating agent in an amount of 0.001 weight percent to 10 weight percent of the composition, wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTPA), deferoxamine mesylate or free bases, hydrates, solvates, crystalline polymorphs, amorphous forms or pharmaceutically acceptable salts thereof.

9. The method of claim 8 , wherein the cardiovascular disorder is at least one of hypertension, coronary artery disease, angina, arrhythmia or a blood circulatory condition.

10. The method of claim 8 , wherein (i) the composition is a preservative-free solution for injection; (ii) the composition is a sterile solution for injection; (iii) the composition is a lyophilized powder which can be reconstituted in water, saline, dextrose or mixtures thereof for injection; or (iv) the composition is in a sterile bag for intravenous infusion.

11. The method of claim 8 , wherein the nicardipine is nicardipine hydrochloride.

12. The method of claim 8 , wherein the chelating agent comprises 0.004 to 10 weight percent of the composition.

13. The method of claim 11 , wherein the chelating agent is edetate disodium (EDTA disodium).

14. The method of claim 13 , wherein the edetate disodium comprises 0.004 weight percent to about 0.04 weight percent of the composition.

15. The method of claim 11 , wherein the composition comprises impurities of nicardipine, the impurities comprising at least one of 3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate, nicardipine monoacid, n-benzyl-n-methyl-ethanolamine or mixtures thereof.

16. A method of preparing a stable pharmaceutical composition of nicardipine, the method comprising providing a chelating agent in an amount of 0.001 weight percent to 10 weight percent of the composition and mixing the chelating agent with the nicardipine in an amount of at least 0.1 weight percent of the composition to form the stable pharmaceutical composition, wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTPA), deferoxamine mesylate or free bases, hydrates, solvates, crystalline polymorphs, amorphous forms or pharmaceutically acceptable salts thereof.

17. The method of claim 16 , wherein the nicardipine is nicardipine hydrochloride.

18. A pharmaceutical composition comprising nicardipine hydrochloride in an amount of 0.1 weight percent to 5.0 weight percent of the composition, a co-solvent comprising sorbitol, mannitol, xylitol, propylene glycol, polyethylene glycol, ethanol, water or a combination thereof, the co-solvent in an amount that is 0.1 to 5 weight percent of the composition, a buffering agent comprising citric acid, anhydrous citric acid, citric acid monohydrate, sodium hydroxide or a combination thereof, the buffering agent in an amount that is 0.01 to 5.0 weight percent of the composition, and a chelating agent in an amount of 0.001 weight percent to 10 weight percent of the composition, wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTPA), deferoxamine mesylate or free bases, hydrates, solvates, crystalline polymorphs, amorphous forms or pharmaceutically acceptable salts thereof.

19. The composition of claim 1 , wherein the composition comprises 0.01 weight percent to 2.08 weight percent total impurities after storing the composition in an atmosphere comprising at least 5 percent oxygen for 3 months.

20. The composition of claim 1 , wherein the nicardipine is in the composition in an amount of 0.1 weight percent to 5.0 weight percent.

21. The method of claim 8 , wherein the nicardipine is in the composition in an amount of 0.1 weight percent to 5.0 weight percent.

22. The method of claim 16 , wherein the nicardipine is in the composition in an amount of 0.1 weight percent to 5.0 weight percent.

23. A pharmaceutical composition consisting essentially of nicardipine hydrochloride in an amount of 0.1 weight percent to 5.0 weight percent of the composition, a co-solvent comprising sorbitol, mannitol, xylitol, propylene glycol, polyethylene glycol, ethanol, water or a combination thereof, the co-solvent in an amount that is 0.1 to 5 weight percent of the composition, a buffering agent comprising citric acid, anhydrous citric acid, citric acid monohydrate, sodium hydroxide or a combination thereof, the buffering agent in an amount that is 0.01 to 5.0 weight percent of the composition, and a chelating agent in an amount of 0.001 weight percent to 10 weight percent of the composition, wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTPA), deferoxamine mesylate or free bases, hydrates, solvates, crystalline polymorphs, amorphous forms or pharmaceutically acceptable salts thereof.

24. The composition of claim 1 , wherein the nicardipine is in the composition as a pharmaceutically acceptable salt.

25. The composition of claim 1 , wherein the nicardipine is in the composition as a free base.

26. The method of claim 8 , wherein the nicardipine is in the composition as a pharmaceutically acceptable salt.

27. The method of claim 8 , wherein the nicardipine is in the composition as a free base.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2021
From: WEHRUNG, DANIEL WALTER; ZHONG, MENG; PATEL, SARAL PINKAL; RAYAPROLU, BINDHU MADHAVI
To: AMERICAN REGENT, INC.
Reel/Frame 057692/0553 →
Continuity (3)
Continuation 16815776 · Mar 11, 2020
Provisional Application 62885704 · Aug 12, 2019
Related Publication 20220016097A1 · Jan 20, 2022
References Cited (52)
US 3985758A · Murakami et al. · 1976 [cited by applicant]
US 5164405A · McFarlane · 1992 [cited by applicant]
US 5198226A · MacFarlane et al. · 1993 [cited by applicant]
US 5519012A · Fercej-Temeljotov · 1996 [cited by examiner]
US 6265392B1 · Abrahamson et al. · 2001 [cited by applicant]
US 7612102B2 · Duncan et al. · 2009 [cited by applicant]
US 7659291B2 · Duncan et al. · 2010 [cited by applicant]
US 9549994B2 · Gupta et al. · 2017 [cited by applicant]
US 10478453B1 · Maloney et al. · 2019 [cited by applicant]
US 20070112041A1 · Bhowmick · 2007 [cited by examiner]
US 20100022602A1 · Gupta et al. · 2010 [cited by applicant]
US 20120088804A1 · Motheram · 2012 [cited by examiner]
US 20120214761A1 · Gupta et al. · 2012 [cited by applicant]
US 20140206643A1 · Gupta et al. · 2014 [cited by applicant]
US 20170247460A1 · Geiger · 2017 [cited by applicant]
CN 102397245A · 2012 [cited by examiner]
CN 102397245 · 2013 [cited by applicant]
CN 105079010A · 2015 [cited by examiner]
GB 2228412A · 1990 [cited by applicant]
GB 2228412 · 1990 [cited by applicant]
RU 2013133938A · 2015 [cited by applicant]
RU 2013133938 · 2016 [cited by applicant]
WO 2012051116A1 · 2012 [cited by applicant]
WO 2012051116 · 2012 [cited by applicant]
WO 2014178065A1 · 2014 [cited by applicant]
WO 2014178065 · 2014 [cited by applicant]
WO 2017117268A1 · 2017 [cited by applicant]
WO 2017117268 · 2017 [cited by applicant]
CN-102397245-A machine translation (Year: 2012). [cited by applicant]
CN-105079010-A machine translation (Year: 2015). [cited by applicant]
PubChem1 https://pubchem.ncbi.nlm.nih.gov/compound/Sorbitol (Year: 2020). [cited by applicant]
PubChem2 https://pubchem.ncbi.nlm.nih.gov/compound/Citric-acid-monohydrate (Year: 2020). [cited by applicant]
Cataldi, M. and Bruno, F. “1,4 Dihydropyridines: The Multiple Personalities of a Blockbuster Drug Family,” Translational Medicine @ UniSa, ISSN 2239-9747, 2012, 4(2): 12-26. [cited by applicant]
“Therapeutic Class Overview Calcium-Channel Blocking Agents (Dihydropyridines),” University of Massachusetts Medical School, 2016, pp. 1-5. [cited by applicant]
Cardene IV prescribing information package insert, EKR Therapeutics, Inc., Jan. 2019, 8 pages. [cited by applicant]
Bhupendrasinh, K. V., et al. “Identification and Characterization of a Novel Potential Degradant and Development and Validation of Stability-Indicating RP-LC Method for Nicardipine Impurities in Injectable Dosage Form,”… [cited by applicant]
Bonferoni, M.C., et al. “Photostability evaluation of nicardipine HCI solutions,” International Journal of Pharmaceutics, vol. 80 (1992) p. 109-117. [cited by applicant]
Baranda, Ana B., et al. “Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples,” Forensic Science International, vol. 156 (2006) pp. 23-24. [cited by applicant]
Shudo, Norimasa, et al. “Two Pyridine Analogues with More Effective Ability to Reverse Multidrug Resistance and with Lower Calcium Channel Blocking Activity Than Their Dihydropyridine Counterparts,” Cancer Research. vol… [cited by applicant]
Committee for Proprietary Medicinal Products (CPMP), “Note for Guidance on Excipients, Antioxidants and Antimicrobial Preservatives in the Dossier for Application for Marketing Authorisation of a Medicinal Product,” The… [cited by applicant]
Mozziconacci, O., et al. “Metal-Catalyzed Oxidation of Protein Methionine Residues in Human Parathyroid Hormone (1-34): Formation of Homocysteine and a Novel Methionine-Dependent Hydrolysis Reaction,” Mol Pharm. Feb. 4,… [cited by applicant]
Gutteridge, John M.C., “Ferrous ion-EDTA-stimulated phospholipid peroxidation—A reaction changing from alkoxyl-radical-to hydroxyl-radical-dependent initiation,” Biochem. J. (1984) vol. 224, pp. 697-701. [cited by applicant]
“5.1.3 Efficacy of Antimicrobial Preservation,” European Pharmacopoeia 7.0, Jan. 2011, retrieved from the Internet on Mar. 11, 2020 at url: https://www.drugfuture.com/Pharmacopoeia/EP7/DATA/50103E.PDF. [cited by applicant]
“Microbial Tests (51) Antimicrobial Effectiveness Testing” The United States Pharmacopeial Convention, 2011, retrieved from the Internet on Mar. 11, 2020 at url: https://www.drugfuture.com/Pharmacopoeia/usp35/PDF/0052-0… [cited by applicant]
“Chapter IV Nicardipine Injection Method Development and Method Validation,” retrieved from the Internet on Mar. 1, 10, 2020 from URL: https://shodhganga.inflibnet.ac.in/bitstream/10603/19305/14/14_chapter-iv%20nicardip… [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority (ISA/EPO) dated Nov. 13, 2020 in corresponding International Application No. PCT/US2020/045758 filed Aug. 11, 2020. [cited by applicant]
Exhibit B. Andersson, Maria M., et al. Stabilizing effect of chemical additives against oxidation of lactate dehydrogenase. Biotechnol. Appl. Biochem. (2000) vol. 32, pp. 145-153. [cited by applicant]
Exhibit C. Ji, Junyan A., et al. Biotechnology. Mehtionine, Tryptophan, and Histidine Oxidation in a Model Protein, PTH: Mechanisms and Stabilization. J Pharm Sci, Dec. 2009 vol. 98, No. 12., pp. 4485-4500. [cited by applicant]
Exhibit D. Bee, Jared S., et al. Precipitation of a Monoclonal Antibody by Soluble Tungsten. J Pharm Sci. Sep. 2009, vol. 98, No. 9, pp. 3290-3301. [cited by applicant]
Exhibit E. Mozziconacci, O., et al. Metal-Catalyzed Oxidation of Protein Methionine Residues in Human Parathyroid Hormone (1-34): Formation of Homocysteine and a Novel Methionine-Dependent Hydrolysis Reaction. Mol Pharm… [cited by applicant]
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued Feb. 8, 2022 by the Patent Cooperation Treaty and the International Searching Authority in Internatio… [cited by applicant]
A translation of Tables 2 and 3 from Chinese Patent Publication No. CN 102397245 A (Apr. 4, 2012). [cited by applicant]